7 t h S u m m e r S c h o o l o f t h e H e l l e n i c A t h e r o s c l e r o s i s S o c i e t y Lifestyle and pharmacological interventions for the management of cardiovascular disease: dilemmas and perspectives June 26 – 28, 2014, Crowne Plaza Hotel, Athens, Greece SCIENTIFIC PROGRAM Thursday, June 26, 2014
Welcome address by the coordinators of the Summer School.
E. Liberopoulos (Ioannina, Greece) – K. Tziomalos (Thessaloniki, Greece). Welcome address by the President of the Hellenic Atherosclerosis Society. E. Ganotakis (Heraklion, Greece).
Lifestyle recommendations for the primary prevention of cardiovascular disease. C. Kastorini (Athens, Greece). Discussion with the participants on multiple choice questions.
Weight loss: how important and how feasible? M. Yannakoulia (Athens, Greece). Discussion with the participants on multiple choice questions.
The impact of diet composition in macronutrients on weight loss. E. Bathrellou (Athens, Greece).
Discussion with the participants on multiple choice questions.
Mediterranean diet as a tool for the management and prevention of cardiovascular disease.
M. Kontogianni (Athens, Greece).
Discussion with the participants on multiple choice questions.
Dietary management of hypertension. Κ. Karatzi (Athens, Greece).
Discussion with the participants on multiple choice questions.
Friday, June 27, 2014
Dietary targets in type 2 diabetes mellitus. Μ. Karipidou (Athens, Greece). Discussion with the participants on multiple choice questions.
The role of omega-3 fatty acids in the secondary and tertiary prevention of cardiovascular disease. P. Detopoulou (Athens, Greece). Discussion with the participants on multiple choice questions.
The role of dietary supplements in the prevention and treatment of cardiovascular disease. Τ. Nomikos (Athens, Greece). Discussion with the participants on multiple choice questions.
Bioactive nutrients with antioxidant, antithrombotic and antiinflammatory action. Ε. Fragopoulou (Athens, Greece). Discussion with the participants on multiple choice questions.
Exercise recommendations in patients with cardiovascular disease: type and intensity. Κ. Anastasiou (Athens, Greece).
Discussion with the participants on multiple choice questions.
Efficacy of comprehensive smoking cessation programs.
P. Katsaounou (Athens, Greece). Discussion with the participants on multiple choice questions.
Lipid-lowering treatment for the reduction of residual cardiovascular risk after achieving LDL targets with a statin: addition of fenofibrate or omega-3 fatty acids? V. Athyros (Thessaloniki, Greece). Discussion with the participants on multiple choice questions.
Lipid-lowering treatment in patients who do not achieve LDL targets with the maximal tolerated dose of a potent study: addition of ezetimibe or colesevelam? M. Elisaf (Ioannina, Greece). Discussion with the participants on multiple choice questions.
Antiplatelet treatment in patients with an acute coronary syndrome: aspirin combined with clopidogrel, prasugrel or ticagrelor? V. Nikolaou (Athens, Greece). Discussion with the participants on multiple choice questions.
Antiplatelet treatment in patients with a recurrent cardiovascular treatment despite treatment with antiplatelets. A. Tselepis (Ioannina, Greece). Discussion with the participants on multiple choice questions.
Anticoagulant treatment in patients with atrial fibrillation: warfarin or novel anticoagulants? C. Pitsavos (Athens, Greece). Discussion with the participants on multiple choice questions.
Medical research methodology. D. Panagiotakos (Athens, Greece).
Discussion with the participants on multiple choice questions.
Should we evaluate the presence of subclinical atherosclerosis in patients without established cardiovascular disease? Foreigner speaker (TBD). Discussion with the participants on multiple choice questions. Saturday, June 28, 2014
Antidiabetic treatment in patients who do not achieve HbA1c targets despite treatment with metformin. Α. Melidonis (Athens, Greece). Discussion with the participants on multiple choice questions.
Intensification of insulin treatment in patients with diabetes mellitus: basal-bolus or premixed insulin-based regimens? S. Pappas (Athens, Greece). Discussion with the participants on multiple choice questions.
hydrochlorothiazide, chlorthalidone or indapamide? V. Kotsis (Thessaloniki, Greece). Discussion with the participants on multiple choice questions.
Inhibition of renin-angiotensin-aldosterone system in patients with hypertension: angiotensin converting enzyme inhibitors or angiotensin receptor blockers? A. Achimastos (Athens, Greece). Discussion with the participants on multiple choice questions.
Antihypertensive treatment in a patient with uncontrolled hypertension despite monotherapy with an inhibitor of the renin- angiotensin-aldosterone system: addition of a diuretic or a calcium channel blocker? A. Karagiannis (Thessaloniki, Greece).
Discussion with the participants on multiple choice questions.
A patient with postprandial hyperglycemia despite treatment with basal insulin and metformin: addition of a dipeptidyl-peptidase IV inhibitor, a glucagon-like peptide-1 analog or prandial insulin? S. Iraklianou (Athens, Greece). Discussion with the participants on multiple choice questions.
New anticoagulants for the treatment of deep vein thrombosis.
E. Liberopoulos (Ioannina, Greece). Discussion with the participants on multiple choice questions.
Sodium-glucose linked transporter inhibitors in the management of type 2 diabetes mellitus. T. Alexandridis (Patras, Greece). Discussion with the participants on multiple choice questions. 17:15 – 17:45:
New agents in the management of hypercholesterolemia: Cholesteryl ester transfer protein inhibitors, mipomersen and lomitapide. K. Tziomalos (Thessaloniki, Greece). Discussion with the participants on multiple choice questions.
New agents in the management of hypercholesterolemia: pro- protein convertase subtilisin kexin 9 inhibitors. Foreigner speaker (TBD). Discussion with the participants on multiple choice questions.
How to write a paper. D. Mikhailidis (London, UK). Discussion with the participants on multiple choice questions. End of Summer School
Einschätzung des Robert Koch-Instituts zur Situation der Schweinegrippe Stand 27.04.2009, 09:00 Uhr In den USA sind 20 Fälle von Schweine-Influenza A/H1N1 beim Menschen entdeckt worden: New York 8 Fälle, Kalifornien 7 Fälle, Texas 2 Fälle, Kansas 2 Fälle, Ohio 1 Fall. Die Symptomatik dieser Fälle ist ähnlich wie bei saisonaler Influenza; ein Patient wurde im Krankenhaus behandelt,
General Information - Influenza Vaccination The Disease: Influenza (flu) is caused by viruses. The fever, chills, headache, dry cough and muscle aches of flu may last from several days to more than a week, but complete recovery is usual. Certain groups of people, however, are much more likely to suffer major complications if they get the flu. People over age 65, residents of nursing hom